Administering gamma-hydroxybutyrate compositions with divalproex sodium

Introduction to administering gamma-hydroxybutyrate compositions

Administering gamma-hydroxybutyrate compositions with divalproex sodium addresses a critical unmet need in the treatment of narcolepsy and related central nervous system disorders. Traditionally, clinicians reduce gamma-hydroxybutyrate doses when divalproex sodium is co-administered because valproate increases systemic exposure. However, such reductions may compromise symptom control. Therefore, novel formulation strategies now aim to enable full-dose co-administration without increasing adverse effects. Moreover, administering gamma-hydroxybutyrate compositions in optimized oral dosage forms improves therapeutic consistency and patient convenience. As a result, affected consumers may benefit from better sleep consolidation, reduced daytime sleepiness, and improved quality of life. Additionally, advanced release profiles create opportunities for safer long-term therapy in vulnerable patient populations.

What patent US20250387361A1 is about?

Patent US20250387361A1 discloses methods and pharmaceutical compositions for administering gamma-hydroxybutyrate compositions together with divalproex sodium without requiring dose adjustment. The publication focuses on oral gamma-hydroxybutyrate formulations, including sodium oxybate, intended for treating narcolepsy symptoms such as cataplexy and excessive daytime sleepiness. Historically, valproate increases gamma-hydroxybutyrate exposure, which raises safety concerns. Consequently, current labeling requires dose reduction. In contrast, the disclosed invention solves this limitation through carefully engineered modified-release dosage forms.

Specifically, the publication describes compositions that combine immediate-release and modified-release fractions within a single dose. As a result, the formulation delivers a rapid onset of action while maintaining sustained plasma concentrations over several hours. Moreover, the inventors define pharmacokinetic targets that ensure comparable bioavailability whether or not divalproex sodium is present. Therefore, patients can receive therapeutically effective doses of both agents concurrently. Additionally, the compositions reduce peak plasma levels, which helps limit central nervous system side effects.

The patent further explains that the modified-release profiles remain stable under fed conditions and in the presence of alcohol. Consequently, administering gamma-hydroxybutyrate compositions becomes more flexible and predictable in real-world use. Furthermore, the disclosure emphasizes reproducible manufacturing and consistent dose performance. Together, these features simplify clinical management and support safer combination therapy for patients who require both gamma-hydroxybutyrate and divalproex sodium.

Role of CELLETS® in administering gamma-hydroxybutyrate compositions

This patent highlights the use of CELLETS® as an enabling technology within the described formulations. CELLETS® are spherical microcrystalline cellulose cores that serve as uniform carriers for drug layering and functional coatings. Importantly, these cores allow precise control over particle size and surface characteristics. As a result, manufacturers can apply gamma-hydroxybutyrate and polymer coatings with high reproducibility. Moreover, CELLETS® support the creation of distinct immediate-release and modified-release populations within one dosage form.

By using CELLETS®, such as Cellets® 90, Cellets® 100 or Cellets® 127, the formulation achieves predictable release kinetics and robust mechanical stability. Consequently, the dosage form withstands handling, encapsulation, and gastrointestinal transit. Additionally, CELLETS® help maintain consistent drug release despite variations in gastric pH or food intake. Therefore, administering gamma-hydroxybutyrate compositions becomes safer and more reliable, particularly in combination therapy settings.

A typical gamma-hydroxybutyrate formulation with CELLETS®

The layer deposited onto the spherical microcrystalline cellulose beads comprises the immediate release gamma-hydroxybutyrate. In an embodiment, the layer also comprises a binder. Resultingly, a typical formulation of an immediate-release particles comprise 80.75% w/w of gamma-hydroxybutyrate, 4.25% w/w of a binder and 15% of microcrystalline cellulose spheres (Cellets® 127).

Conclusion and outlook

In conclusion, administering gamma-hydroxybutyrate compositions with divalproex sodium as described in US20250387361A1 represents a significant advancement in narcolepsy treatment. The disclosed formulations eliminate the need for dose reduction while maintaining safety and efficacy. Moreover, the use of multiparticulate systems and CELLETS® enables precise release control and improved patient outcomes. Looking ahead, these technologies may support broader applications in central nervous system therapeutics. Therefore, future development could extend this approach to other combination therapies that demand stable pharmacokinetics and improved tolerability.

Patent Summary

• Name of Patent: Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
• Patent Number: US20250387361A1
• Year of Patent: 2025
• Patent Holders: Julien Grassot
• Affiliation: Flamel Ireland Ltd